




Novartis: Sealice R&D Multinational Sealice Meeting

Bergen 10th February 2010

John Marshall

Overview of Novartis's activity on Sealice

Optimization of what we have



Changing the 'mind set' regarding how we look for Sealice remedies.



Long term

Second generation best in Class

- New class of active or technology ?
- Significant length of protection ?
- Ease of administration important ?

Medium term

Best in Class


- New Class of active ?
- Prolonged duration of protection ?
- More effective treatment ?
- Ease of administration important ?

Short term

Resistance breaker

- Class of active with knowledge ?
- No durational protection ?
- Does not need to be 'best' treatment?
- < 100% efficacy acceptable ?

Latest from Novartis: HTS ongoing and automated



Concluding remarks

- There is no 'Quick Fix' today
- We do have candidates for the future
- We are doing everything we can to reduce time to 'availability'

Sealice solutions are top priority in Novartis Animal Health

Thank you



Novartis in-house dedicated sealice facility: open 2008